肠道菌群介导的免疫反应在慢性HBV感染中的作用

高慧; 刘守胜; 赵真真; 辛永宁

doi:10.3969/j.issn.1001-5256.2019.11.039

肠道菌群介导的免疫反应在慢性HBV感染中的作用

DOI: 10.3969/j.issn.1001-5256.2019.11.039

1. 青岛大学附属青岛市市立医院感染性疾病科
2. 青岛大学附属青岛市市立医院中心实验室

基金项目:

国家自然科学基金面上项目(31770837)；

详细信息

中图分类号: R512.62
计量
- 文章访问数: 1058
- HTML全文浏览量: 58
- PDF下载量: 342
- 被引次数: 0
出版历程
- 收稿日期: 2019-07-02
- 出版日期: 2019-11-20

Role of intestinal flora-mediated immune response in chronic hepatitis B virus infection

Department of Infectious Diseases,Qingdao Municipal Hospital Affiliated to Qingdao University

Research funding:

摘要

摘要: HBV感染可引起急性或慢性肝损伤,而HBV相关的肝硬化和肝细胞癌通常会导致病死率增加,其发病机制可能与免疫反应相关。肠道菌群在宿主的代谢和免疫调节中扮演着重要的角色,对"肠肝轴"和肠道菌群的研究发现,肠道微生物群的结构变化、细菌易位以及由此产生的免疫损伤会影响慢性乙型肝炎基础上肝脏炎症的发生和发展。总结和讨论肠道菌群在慢性乙型肝炎中的免疫作用,并探讨基于肠道菌群的HBV感染的潜在治疗方法。
- 乙型肝炎,慢性 /
- 胃肠道微生物组 /
- 免疫调节 /
- 粪便微生物群移植
Abstract: Hepatitis B virus( HBV) infection can cause acute or chronic liver injury. Chronic hepatitis B( CHB)-related liver cirrhosis and hepatocellular carcinoma usually lead to an increase in mortality,and their pathogenesis may be associated with immune response. Intestinal flora plays an important role in host metabolism and immune regulation,and the studies on“gut-liver axis”and intestinal flora have shown that the structural change of intestinal flora,bacterial translocation,and related immunologic injury may affect the development and progression of liver inflammation on the basis of CHB. This article summarizes and discusses the immunological role of intestinal flora in CHB and explores the potential treatment methods for HBV infection based on intestinal flora.
- hepatitis B,chronic /
- gastrointestinal microbiome /
- immunomodulation /
- fecal microbiota transplantation

HTML全文

参考文献(39)

[1] LOZANO R,NAGHAVI M,FOREMAN K,et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990and 2010:A systematic analysis for the Global Burden of Disease Study 2010[J]. Lancet,2012,380(9859):2095-2128.

[2] ADOLPH TE,GRANDER C,MOSCHEN AR,et al. Liver-microbiome axis in health and disease[J]. Trends Immunol,2018,39(9):712-723.

[3] CHOU HH,CHIEN WH,WU LL,et al. Age-related immune clearance of hepatitis B virus infection requires the establishment of gut microbiota[J]. Proc Natl Acad Sci U S A,2015,112(7):2175-2180.

[4] PRENDERGAST AJ,KLENERMAN P,GOULDER PJ. The impact of differential antiviral immunity in children and adults[J].Nat Rev Immunol,2012,12(9):636-648.

[5] PROTZER U,MAINI MK,KNOLLE PA. Living in the liver:Hepatic infections[J]. Nat Rev Immunol,2012,12(3):201-213.

[6] MCCLARY H,KOCH R,CHISARI FV,et al. Relative sensitivity of hepatitis B virus and other hepatotropic viruses to the antiviral effects of cytokines[J]. J Virol,2000,74(5):2255-2264.

[7] WOHLLEBER D,KASHKAR H,GARTNER K,et al. TNF-induced target cell killing by CTL activated through cross-presentation[J]. Cell Rep,2012,2(3):478-487.

[8] EBERT G,PRESTON S,ALLISON C,et al. Cellular inhibitor of apoptosis proteins prevent clearance of hepatitis B virus[J].Proc Natl Acad Sci U S A,2015,112(18):5797-5802.

[9] PEERIDOGAHEH H,MESHKAT Z,HABIBZADEH S,et al.Current concepts on immunopathogenesis of hepatitis B virus infection[J]. Virus Res,2018,245:29-43.

[10] CHISARI FV,FERRARI C. Hepatitis B virus immunopathogenesis[J]. Annu Rev Immunol,1995,13:29-60.

[11] XIA Y,STADLER D,LUCIFORA J,et al. Interferon-gamma and tumor necrosis factor-alpha produced by T cells reduce the HBV persistence form,cccDNA,without cytolysis[J].Gastroenterology,2016,150(1):194-205.

[12] FOUTS DE,TORRALBA M,NELSON KE,et al. Bacterial translocation and changes in the intestinal microbiome in mouse models of liver disease[J]. J Hepatol,2012,56(6):1283-1292.

[13] SENDER R,FUCHS S,MILO R. Revised estimates for the number of human and bacteria cells in the body[J]. PLo S Biol,2016,14(8):e1002533.

[14] ATARASHI K,HONDA K. Microbiota in autoimmunity and tolerance[J]. Curr Opin Immunol,2011,23(6):761-768.

[15] LIU JQ,ZHOU SM. Research advances in intestinal flora in nonalcoholic fatty liver disease[J]. J Clin Hepatol,2017,33(12):2453-2456.(in Chinese)刘嘉琪，周少明．非酒精性脂肪性肝病肠道菌群的研究进展[J]．临床肝胆病杂志，2017,33(12):2453-2456.

[16] LIU XY,KONG GM,QIAN F. Research progress of probiotics in the treatment of inflammatory bowel disease[J]. Chin J Med Offic,2018,46(7):840-842.(in Chinese)刘心意，孔桂美，钱锋．益生菌治疗炎症性肠病研究进展[J]．临床军医杂志，2018,46(7):840-842.

[17] ZHANG J,FENG Z,LIU P,et al. Research progress on interaction between intestinal flora and liver transplantation[J].Ogran Transplantation,2017,8(5):399-401.(in Chinese)张静，冯哲，刘鹏，等．肠道菌群与肝移植相互作用研究进展[J]．器官移植，2017,8(5):399-401.

[18] GHOSH G,JESUDIAN AB. Small intestinal bacterial overgrowth in patients with cirrhosis[J]. J Clin Exp Hepatol,2019,9(2):257-267.

[19] XING HC,LI LJ,XU KJ,et al. Protective role of supplement with foreign Bifidobacterium and Lactobacillus in experimental hepatic ischemia-reperfusion injury[J]. J Gastroenterol Hepatol,2006,21(4):647-656.

[20] CHEN Y,YANG F,LU H,et al. Characterization of fecal microbial communities in patients with liver cirrhosis[J]. Hepatology,2011,54(2):562-572.

[21] HUANG XY,LI GP,KOU JG,et al. Relationship between intestinal dysbacteriosis and Child-Pugh classification in patients with cirrhosis[J]. J Clin Hepatol,2015,31(3):392-395.(in Chinese)黄晓宇，李刚平，寇继光，等．肝硬化患者肠道菌群失调与Child-Pugh分级的关系[J]．临床肝胆病杂志，2015,31(3):392-395.

[22] CHEN Y,CHEN Z,GUO R,et al. Correlation between gastrointestinal fungi and varying degrees of chronic hepatitis B virus infection[J]. Diagn Microbiol Infect Dis,2011,70(4):492-498.

[23] CAMPION D,GIOVO I,PONZO P,et al. Dietary approach and gut microbiota modulation for chronic hepatic encephalopathy in cirrhosis[J]. World J Gastroenterol,2019,11(6):489-512.

[24] RIORDAN SM,WILLIAMS R. Gut flora and hepatic encephalopathy in patients with cirrhosis[J]. N Engl J Med,2010,362(12):1140-1142.

[25] GARCIA-TSAO G,WIEST R. Gut microflora in the pathogenesis of the complications of cirrhosis[J]. Best Pract Res Clin Gastroenterol,2004,18(2):353-372.

[26] PIANO S,BROCCA A,ANGELI P. Renal function in cirrhosis:A critical review of available tools[J]. Semin Liver Dis,2018,38(3):230-241.

[27] KANG Y,CAI Y. Gut microbiota and hepatitis-B-virusinduced chronic liver disease:Implications for faecal microbiota transplantation therapy[J]. J Hosp Infect,2017,96(4):342-348.

[28] FRAZIER TH,DIBAISE JK,McCLAIN CJ. Gut microbiota,intestinal permeability,obesity-induced inflammation,and liver injury[J]. JPEN J Parenter Enteral Nutr,2011,35(Suppl 5):14s-20s.

[29] SEKI E,SCHNABL B. Role of innate immunity and the microbiota in liver fibrosis:Crosstalk between the liver and gut[J]. J Physiol,2012,590(3):447-458.

[30] BORRELLI A,BONELLI P,TUCCILLO FM,et al. Role of gut microbiota and oxidative stress in the progression of non-alcoholic fatty liver disease to hepatocarcinoma:Current and innovative therapeutic approaches[J]. Redox Biol,2018,15:467-479.

[31] GAO K,LIU L,WANG HF. Advances in immunomodulation of microbial unmethylated CpG DNA on animal intestinal tract-a review[J]. Acta Microbiol Sin,2015,55(5):543-550.(in Chinese)高侃，刘丽，汪海峰．微生物未甲基化CpG DNA对动物肠道的免疫调节作用[J]．微生物学报，2015,55(5):543-550.

[32] IGNACIO A,MORALES CI,CAMARA NO,et al. Innate sensing of the gut microbiota:Modulation of inflammatory and autoimmune diseases[J]. Front Immunol,2016,7:54.

[33] VARAKANAHALLI S,SHARMA BC,SRIVASTAVA S,et al. Secondary prophylaxis of hepatic encephalopathy in cirrhosis of liver:A double-blind randomized controlled trial of L-ornithine L-aspartate versus placebo[J]. Eur J Gastroenterol Hepatol,2018,30(8):951-958.

[34] LIU GY,CHEN HH,WANG X,et al. Advances in research on antibiotic resistance of Bifidobacteria[J]. Chin J Microecol,2019,31(3):360-364.(in Chinese)刘桂扬，陈华海，王欣，等．双歧杆菌抗生素耐药性研究进展[J]．中国微生态学杂志，2019,31(3):360-364.

[35] SCHUIJT TJ,LANKELMA JM,SCICLUNA BP,et al. The gut microbiota plays a protective role in the host defence against pneumococcal pneumonia[J]. Gut,2016,65(4):575-583.

[36] GEVA-ZATORSKY N,SEFIK E,KUA L,et al. Mining the human gut microbiota for immunomodulatory organisms[J].Cell,2017,168(5):928-943.

[37] GUNALTAY S,RADEMACHER L,HULTGREN E,et al. Clinical and immunologic effects of faecal microbiota transplantation in a patient with collagenous colitis[J]. World J Gastroenterol,2017,23(7):1319-1324.

[38] NISHIDA A,IMAEDA H,OHNO M,et al. Efficacy and safety of single fecal microbiota transplantation for Japanese patients with mild to moderately active ulcerative colitis[J]. J Gastroenterol,2017,52(4):476-482.

[39] REN YD,YE ZS,YANG LZ,et al. Fecal microbiota transplantation induces hepatitis B virus e-antigen(HBe Ag)clearance in patients with positive HBe Ag after long-term antiviral therapy[J]. Hepatology,2017,65(5):1765-1768.

施引文献

资源附件(0)

访问统计